Excedrin Sales Up 5% Worldwide In Third Quarter, Bufferin Up 19%
This article was originally published in The Tan Sheet
Executive Summary
Worldwide sales of Bristol-Myers Squibb's Excedrin increased 5% to $61 mil. in the third quarter. In the U.S., Excedrin sales were up 7% to $59 mil., while international revenues dropped 33% to $2 mil.